Clinical and economic evaluation of the effectiveness of drug therapy for patients with CRC, taking into account the molecular genetic characteristics of the tumor

Konstantinova Julia Sergeevna, Krashenkov Oleg Pavlovich, Poyarkov Stanislav Vladimirovich, Veselovsky Egor Mikhailovich

A deeper understanding of the biology of colorectal cancer (CRC) in recent years has contributed to the identification of new biomarkers that can serve as the basis for the precision treatment of the metastatic stages of this disease. This review will provide an analysis of the results of studies on the pharmacoeconomic assessment of molecular biomarkers (MBM) and their use in stratification of patients with CRC: 1) the dihydropyrimidine dehydrogenase gene (DPYD) associated with increased toxicity of 5-fluorouracil (5-FU); 2) gene 1 of uridine-5'-diphosphoglucuronosyltransferase of the A1 family (UGT1A1) associated with the response to irinotecan; 3) genes of the RAS / RAF family for stratification of patients into chemo- or anti-EGFR therapy groups; 4) multigenic expression (Oncotype Dx) associated with treatment resistance and increased toxicity of certain chemotherapy regimens.

Keywords:colorectal cancer, molecular biomarkers, precision medicine, tumor genome.